Prolyl hydroxylase domain inhibitors: A route to HIF activation and neuroprotection

Antioxidants and Redox Signaling

Volumn 12, Issue 4, 2010, Pages 459-480

  Harten, Sarah K ^a   Ashcroft, Margaret ^a   Maxwell, Patrick H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ADRENOMEDULLIN; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; COBALT CHLORIDE; ENZYME INHIBITOR; ERYTHROPOIETIN; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; FG 4497; FLUNARIZINE; GAVESTINEL; GLUTAMATE RECEPTOR ANTAGONIST; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT; NIMODIPINE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE INHIBITOR; PROTEIN ZO1; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGITATION; ANGIOGENESIS; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN METABOLISM; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELIRIUM; DRUG SAFETY; DRUG TOLERABILITY; ENERGY METABOLISM; ENZYME INHIBITION; EXCITOTOXICITY; GLYCOLYSIS; HALLUCINATION; HUMAN; HYPOXIA; INFLAMMATION; IRON METABOLISM; NERVE CELL DIFFERENTIATION; NERVE REGENERATION; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STROKE; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; CALCIUM CHANNEL BLOCKERS; CYTOPROTECTION; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICAL SCAVENGERS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; ISCHEMIC PRECONDITIONING; MICE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROCOLLAGEN-PROLINE DIOXYGENASE; RATS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; STROKE;

EID: 75149124682     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2870     Document Type: Review

References (280)

1. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308: 81-106, 1994.
2. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349: 1569-1581, 1997
3. North American glycine antagonist in neuroprotection investigators. https://www.fkpi.com/release, 2000.
4. Tirilazad mesylate in acute ischemic stroke: A systematic review. Tirilazad International Steering Committee. Stroke 31: 2257-2265, 2000.
5. Adelman DM, Maltepe E, and Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 13: 2478-2483, 1999.
6. Airley RE and Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in can-cer: Novel pathways and targets for anticancer therapeutics. Chemotherapy 53: 233-256, 2007.
7. Aminova LR, Siddiq A, and Ratan RR. Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the transcriptional activator, HIF-1alpha, in a mouse hippo-campal neuronal line. Antioxid Redox Signal 10: 1989-1998, 2008.
8. Anderson JM, Van Itallie CM, and Fanning AS. Setting up a selective barrier at the apical junction complex. Curr Opin Cell Biol 16: 6, 2004.
9. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, and Prchal JT. Disruption of oxygen homeostasis underlies congenital Chuvash poly-cythemia. Nat Genet 32: 614-621, 2002.
10. Aragones J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH, Lambrechts D, Bishop T, Lafuste P, Diez-Juan A, Harten SK, Van Noten P, De Bock K, Willam C, Tjwa M, Grosfeld A, Navet R, Moons L, Vandendriessche T, De-roose C, Wijeyekoon B, Nuyts J, Jordan B, Silasi-Mansat R, Lupu F, Dewerchin M, Pugh C, Salmon P, Mortelmans L, Gallez B, Gorus F, Buyse J, Sluse F, Harris RA, Gnaiger E, Hespel P, Van Hecke P, Schuit F, Van Veldhoven P, Ratcliffe P, Baes M, Maxwell P, and Carmeliet P. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40: 170-180, 2008.
11. Aronowski J, Strong R, and Grotta JC. Reperfusion injury: Demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 17: 1048-1056, 1997.
12. Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ, and Semenza GL. OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell 17: 503-512, 2005.
13. Ballanyi K. Protective role of neuronal KATP channels in brain hypoxia. J Exp Biol 207: 3201-3212, 2004.
14. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, and Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 27: 6320-6332, 2007.
15. Barger SW, Horster D, Furukawa K, Goodman Y, Kriegl-stein J, and Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA 92: 9328-9332, 1995.
16. Bartrons R and Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 39: 223-229, 2007.
17. Belmadani A, Tran PB, Ren D, Assimacopoulos S, Grove EA, and Miller RJ. The chemokine stromal cell-derived factor-1 regulates the migration of sensory neuron progenitors. J Neurosci 25: 3995-4003, 2005.
18. Bergeron M, Gidday JM, Yu AY, Semenza GL, Ferriero DM, and Sharp FR. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann Neurol 48: 285-296, 2000.
19. Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, and Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 22: 393-403, 2002.
20. Bernaudin M, Tang Y, Reilly M, Petit E, and Sharp FR. Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J Biol Chem 277: 39728-39738, 2002.
21. Blomgren K and Hagberg H. Free radicals, mitochondria, and hypoxia-ischemia in the developing brain. Free Radic Biol Med 40: 388-397, 2006.
22. Blondeau N, Widmann C, Lazdunski M, and Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci 21: 4668-4677, 2001.
23. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo JM, Chamorro A, and Desmet A. Fiblast (trafermin) in acute stroke: Results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 14: 239-251, 2002.
24. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK, and Archer SL. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: Similarities to human pulmonary arterial hypertension. Circulation 113: 2630-2641, 2006.
25. Bracken CP, Whitelaw ML, and Peet DJ. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 60: 1376-1393, 2003.
26. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526-10531, 2000.
27. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1: 409-414, 2005.
28. Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, and Melillo G. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107: 2705-2712, 2006.
29. Cash TP, Pan Y, and Simon MC. Reactive oxygen species and cellular oxygen sensing. Free Radic Biol Med 43: 1219-1225, 2007.
30. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, and Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95: 11715-11720, 1998.
31. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and Schumacker PT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hyp-oxia: A mechanism of O2 sensing. J Biol Chem 275: 25130-25138, 2000.
32. Chen W, Jadhav V, Tang J, and Zhang JH. HIF-1alpha inhibition ameliorates neonatal brain injury in a rat pup hypoxic-ischemic model. Neurobiol Dis 31: 433-441, 2008.
33. Chu K, Jung KH, Kim SJ, Lee ST, Kim J, Park HK, Song EC, Kim SU, Kim M, Lee SK, and Roh JK. Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain. Brain Res 1207: 182-192, 2008.
34. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, and Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol 278: H643-H651, 2000.
35. Colegio OR, Van Itallie CM, McCrea HJ, Rahner C, and Anderson JM. Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am J Physiol Cell Physiol 283: 6, 2002.
36. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Rava-netti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, Greco A, Mangoni M, Bonati A, Rizzoli V, and Giuliani N. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110: 4464-4475, 2007.
37. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, and Keith B. HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570, 2006.
38. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, and Taylor CT. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 103: 18154-18159, 2006.
39. Deli MA. Potential use of tight junction modulators to re-versibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 1788: 892-910, 2009.
40. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, and Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 39: 1774-1778, 2008.
41. Digicaylioglu M and Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641-664, 2001.
42. Dogan A, Suzuki Y, Koketsu N, Osuka K, Saito K, Takayasu M, Shibuya M, and Yoshida J. Intravenous infusion of adrenomedullin and increase in regional cerebral blood flow and prevention of ischemic brain injury after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 17: 19-25, 1997.
43. Du C, Hu R, Csernansky CA, Hsu CY, and Choi DW. Very delayed infarction after mild focal cerebral ischemia: A role for apoptosis? J Cereb Blood Flow Metab 16: 195-201, 1996.
44. Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, and Dubois-Dalcq M. A role for CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia 50: 258-269, 2005.
45. Eckle T, Kohler D, Lehmann R, El Kasmi K, and Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotec-tion: A new paradigm for ischemic preconditioning. Circulation 118: 166-175, 2008.
46. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, and Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495-505, 2002.
47. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, and Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygen-ase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281: 15215-15226, 2006.
48. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94: 4273-4278, 1997.
49. Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gomez-Isla T, Hyman BT, and Moskowitz MA. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 18: 238-247, 1998.
50. Englander EW, Greeley GH, Jr., Wang G, Perez-Polo JR, and Lee HM. Hypoxia-induced mitochondrial and nuclear DNA damage in the rat brain. J Neurosci Res 58: 262-269, 1999.
51. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian ho-mologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
52. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O'Brien TS, and Maxwell PH. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66: 3567-3575, 2006.
53. Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, Sufan RI, Roberts AM, Wilson LA, Betten M, Vandewalle C, Berx G, Marsden PA, Irwin MS, Teh BT, Jewett MA, and Ohh M. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27: 157-169, 2007.
54. Feldman GJ, Mullin JM, and Ryan MP. Occludin: Structure, function and regulation. Adv Drug Deliv Rev 57: 883-917, 2005.
55. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 10, 1996.
56. Foulkes MA, Wolf PA, Price TR, Mohr JP, and Hier DB. The Stroke Data Bank: Design, methods, and baseline characteristics. Stroke 19: 547-554, 1988.
57. Franke CL, Palm R, Dalby M, Schoonderwaldt HC, Hant-son L, Eriksson B, Lang-Jenssen L, and Smakman J. Flunarizine in stroke treatment (FIST): A double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 93: 56-60, 1996.
58. Fu Y, Sun JL, Ma JF, Geng X, Sun J, Liu JR, Song YJ, and Chen SD. The neuroprotection of prodromal transient ischaemic attack on cerebral infarction. Eur J Neurol 15: 797-801, 2008.
59. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, and Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129: 111-122, 2007.
60. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, and Tsukita S. Occludin: A novel integral membrane protein localizing at tight junctions. J Cell Biol 123: 1777-1788, 1993.
61. Furuse M and Tsukita S. Claudins in occluding junctions of humans and flies. Trends Cell Biol 16: 8, 2006.
62. Gage AT and Stanton PK. Hypoxia triggers neuroprotec-tive alterations in hippocampal gene expression via a heme-containing sensor. Brain Res 719: 172-178, 1996.
63. Gale DP, Harten SK, Reid CD, Tuddenham EG, and Maxwell PH. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood 112: 919-921, 2008.
64. Geddes JW, Pettigrew LC, Holtz ML, Craddock SD, and Maines MD. Permanent focal and transient global cerebral ischemia increase glial and neuronal expression of heme oxygenase-1, but not heme oxygenase-2, protein in rat brain. Neurosci Lett 210: 205-208, 1996.
65. Gee CE, Benquet P, Raineteau O, Rietschin L, Kirbach SW, and Gerber U. NMDA receptors and the differential is-chemic vulnerability of hippocampal neurons. Eur J Neu-rosci 23: 2595-2603, 2006.
66. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, and Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118: 781-794, 2004.
67. Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, Yeo GS, McDonough MA, Cunliffe S, McNeill LA, Galvanovskis J, Rorsman P, Robins P, Prieur X, Coll AP, Ma M, Jovanovic Z, Farooqi IS, Sedgwick B, Barroso I, Lindahl T, Ponting CP, Ashcroft FM, O'Rahilly S, and Schofield CJ. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318: 1469-1472, 2007.
68. Ghezzi P and Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11 Suppl 1: S37-44, 2004.
69. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7: 437-448, 2006.
70. Gidday JM, Fitzgibbons JC, Shah AR, and Park TS. Neu-roprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci Lett 168: 221-224, 1994.
71. Glazier SS, O'Rourke DM, Graham DI, and Welsh FA. Induction of ischemic tolerance following brief focal ischemia in rat brain. J Cereb Blood Flow Metab 14: 545-553, 1994.
72. Goldberg Me. 2009. Stroke Trials Registry Internet Stroke Center web site. www.strokecenter.org/trials/.
73. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, and del Zoppo GJ. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 32: 280-299, 2001. (Pubitemid 32063861)
74. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, and Brines M. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99: 9450-9455, 2002.
75. Grabmaier K, de Weijert MC AdW, Verhaegh GW, Schalken JA, and Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23: 5624-5631, 2004.
76. Gravanis I and Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets 12: 159-170, 2008.
77. Greene JG and Greenamyre JT. Bioenergetics and gluta-mate excitotoxicity. Prog Neurobiol 48: 613-634, 1996.
78. Gu YZ, Moran SM, Hogenesch JB, Wartman L, and Brad-field CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7: 205-213, 1998.
79. Guerra-Crespo M, Gleason D, Sistos A, Toosky T, Solaroglu I, Zhang JH, Bryant PJ, and Fallon JH. Transforming growth factor-alpha induces neurogenesis and behavioral improvement in a chronic stroke model. Neuroscience 160: 470-483, 2009.
80. Gunaratnam L, Morley M, Franovic A, de Paulsen N, Me-khail K, Parolin DA, Nakamura E, Lorimer IA, and Lee S. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 278: 44966-44974, 2003.
81. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1: 401-408, 2005.
82. Guzy RD and Schumacker PT. Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. Exp Physiol 91: 807-819, 2006.
83. Haley EC, Jr. High-dose tirilazad for acute stroke (RANT-TAS II). RANTTAS II Investigators. Stroke 29: 1256-1257, 1998.
84. Han ZB, Ren H, Zhao H, Chi Y, Chen K, Zhou B, Liu YJ, Zhang L, Xu B, Liu B, Yang R, and Han ZC. Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 29: 1853-1861, 2008.
85. Hansen AJ. Effect of anoxia on ion distribution in the brain. Physiol Rev 65: 101-148, 1985.
86. Hansen TM, Moss AJ, and Brindle NP. Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. Curr Neurovasc Res 5: 236-245, 2008.
87. Harten SK, Esteban MA, and Maxwell PH. Identification of novel VHL regulated genes by transcriptomic analysis of RCC10 renal carcinoma cells. Adv Enzyme Regul 49: 43-52, 2009.
88. Harten SK, Shukla D, Barod R, Hergovich A, Balda MS, Matter K, Esteban MA, and Maxwell PH. Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. Mol Biol Cell 20: 1089-1101, 2009.
89. Hawkins BT and Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57: 173-185, 2005.
90. Hayashi T, Abe K, Suzuki H, and Itoyama Y. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 28: 2039-2044, 1997.
91. Heiss WD. Ischemic penumbra: Evidence from functional imaging in man. J Cereb Blood Flow Metab 20: 1276-1293, 2000.
92. Helton R, Cui J, Scheel JR, Ellison JA, Ames C, Gibson C, Blouw B, Ouyang L, Dragatsis I, Zeitlin S, Johnson RS, Lipton SA, and Barlow C. Brain-specific knock-out of hypoxia-inducible factor-1alpha reduces rather than increases hypoxic-ischemic damage. J Neurosci 25: 4099-4107, 2005.
93. Hewitson KS, McNeill LA, Elkins JM, and Schofield CJ. The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans 31: 510-515, 2003.
94. Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carme-liet P, and Maxwell PH. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 19: 39-46, 2008.
95. Hill WD, Hess DC, Martin-Studdard A, Carothers JJ, Zheng J, Hale D, Maeda M, Fagan SC, Carroll JE, and Conway SJ. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: Association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 63: 84-96, 2004.
96. Hopfer U, Hopfer H, Jablonski K, Stahl RA, and Wolf G. The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3). J Biol Chem 281: 8645-8655, 2006.
97. Horn J, de Haan RJ, Vermeulen M, and Limburg M. Very Early Nimodipine Use in Stroke (VENUS): A randomized, double-blind, placebo-controlled trial. Stroke 32: 461-465, 2001.
98. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, and Wei L. Transplantation of hypoxia-preconditioned mesenchy-mal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 135: 799-808, 2008.
99. Huang J, Upadhyay UM, and Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol 66: 232-245, 2006.
100. Iihara K, Hashimoto N, Tsukahara T, Sakata M, Yanamoto H, and Taniguchi T. Platelet-derived growth factor-BB, but not-AA, prevents delayed neuronal death after forebrain ischemia in rats. J Cereb Blood Flow Metab 17: 1097-1106, 1997.
101. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, and Semenza GL. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12: 149-162, 1998.
102. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiqui-tylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
103. Jancso G, Cserepes B, Gasz B, Benko L, Ferencz A, Bor-siczky B, Lantos J, Dureja A, Kiss K, Szeberenyi J, and Roth E. Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium. J Cardiovasc Pharmacol 46: 295-301, 2005.
104. Jin K, Mao XO, Batteur SP, McEachron E, Leahy A, and Greenberg DA. Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor. Neuroscience 108: 351-358, 2001.
105. Jin K, Mao XO, Sun Y, Xie L, and Greenberg DA. Stem cell factor stimulates neurogenesis in vitro and in vivo. J Clin Invest 110: 311-319, 2002.
106. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, and Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99: 11946-11950, 2002.
107. Jin KL, Mao XO, and Greenberg DA. Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 97: 10242-10247, 2000.
108. Jones NM and Bergeron M. Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. J Cereb Blood Flow Metab 21: 1105-1114, 2001.
109. Jones NM, Kardashyan L, Callaway JK, Lee EM, and Beart PM. Long-term functional and protective actions of preconditioning with hypoxia, cobalt chloride, and desfer-rioxamine against hypoxic-ischemic injury in neonatal rats. Pediatr Res 63: 620-624, 2008.
110. Joo JD, Kim M, D'Agati VD, and Lee HT. Ischemic preconditioning provides both acute and delayed protection against renal ischemia and reperfusion injury in mice. J Am Soc Nephrol 17: 3115-3123, 2006.
111. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Pae-diatr Suppl 91: 36-42, 2002.
112. Juul SE, Anderson DK, Li Y, and Christensen RD. Ery-thropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 43: 40-49, 1998.
113. Kago T, Takagi N, Date I, Takenaga Y, Takagi K, and Takeo S. Cerebral ischemia enhances tyrosine phosphorylation of occludin in brain capillaries. Biochem Biophys Res Commun 339: 1197-1203, 2006.
114. Kaminogo M, Suyama K, Ichikura A, Onizuka M, and Shibata S. Anoxic depolarization determines ischemic brain injury. Neurol Res 20: 343-348, 1998.
115. Kapinya KJ, Prass K, and Dirnagl U. Isoflurane induced prolonged protection against cerebral ischemia in mice: A redox sensitive mechanism? Neuroreport 13: 1431-1435, 2002.
116. Kaufmann AM, Firlik AD, Fukui MB, Wechsler LR, Jung-ries CA, and Yonas H. Ischemic core and penumbra in human stroke. Stroke 30: 93-99, 1999.
117. Kaur C and Ling EA. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 5: 71-81, 2008.
118. Kenneth NS and Rocha S. Regulation of gene expression by hypoxia. Biochem J 414: 19-29, 2008.
119. Kibel A, Iliopoulos O, DeCaprio JA, and Kaelin WG, Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269: 1444-1446, 1995.
120. Kietzmann T and Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 16: 474-486, 2005.
121. Kim JW, Tchernyshyov I, Semenza GL, and Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185, 2006.
122. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 239: 57-69, 1982.
123. Kirino T and Sano K. Selective vulnerability in the gerbil hippocampus following transient ischemia. Acta Neuro-pathol 62: 201-208, 1984. (Pubitemid 14178596)
124. Kishida T, Stackhouse TM, Chen F, Lerman MI, and Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 55: 4544-4548, 1995.
125. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N, Fukunaga R, Kimura K, Mikoshiba K, et al. 'Ischemic tolerance' phenomenon found in the brain. Brain Res 528: 21-24, 1990.
126. Koditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C, Myllyharju J, Wenger RH, and Katschinski DM. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110: 3610-3617, 2007.
127. Kondo T, Reaume AG, Huang TT, Carlson E, Murakami K, Chen SF, Hoffman EK, Scott RW, Epstein CJ, and Chan PH. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci 17: 4180-4189, 1997. (Pubitemid 27220609)
128. Kondoh M and Yagi K. Tight junction modulators: Promising candidates for drug delivery. Curr Med Chem 14: 2482-2488, 2007.
129. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K, Okada Y, and Ikeda E. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 170: 1389-1397, 2007.
130. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 19: 312-318, 1996.
131. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, and Semenza GL. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66: 2725-2731, 2006.
132. Kumral A, Genc S, Ozer E, Yilmaz O, Gokmen N, Koroglu TF, Duman N, Genc K, and Ozkan H. Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxic-ischemic brain injury. Biol Neonate 89: 205-210, 2006.
133. Kung HC, Hoyert DL, Xu J, and Murphy SL. Deaths: Final data for 2005. Natl Vital Stat Rep 56: 1-120, 2008.
134. Kusumoto M, Dux E, and Hossmann KA. Effect of trophic factors on delayed neuronal death induced by in vitro ischemia in cultivated hippocampal and cortical neurons. Metab Brain Dis 12: 113-120, 1997.
135. Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, Feunteun J, Pouyssegur J, Richard S, and Gardie B. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 359: 2685-2692, 2008.
136. Lakkisto P, Csonka C, Fodor G, Bencsik P, Voipio-Pulkki LM, Ferdinandy P, and Pulkki K. The heme oxygenase in-ducer hemin protects against cardiac dysfunction and ventricular fibrillation in ischaemic/reperfused rat hearts: Role of connexin 43. Scand J Clin Lab Invest 69: 209-218, 2009.
137. Lando D, Peet DJ, Whelan DA, Gorman JJ, and Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861, 2002.
138. Lasley RD, Anderson GM, and Mentzer RM, Jr. Ischaemic and hypoxic preconditioning enhance postischaemic recovery of function in the rat heart. Cardiovasc Res 27: 565-570, 1993.
139. Laudenbach V, Fontaine RH, Medja F, Carmeliet P, Hicklin DJ, Gallego J, Leroux P, Marret S, and Gressens P. Neonatal hypoxic preconditioning involves vascular endothelial growth factor. Neurobiol Dis 26: 243-252, 2007.
140. Lee HT, Chang YC, Tu YF, and Huang CC. VEGF-A/VEGFR-2 signaling leading to cAMP response element-binding protein phosphorylation is a shared pathway underlying the protective effect of preconditioning on neurons and endothelial cells. J Neurosci 29: 4356-4368, 2009.
141. Lee SH, Kim YJ, Lee KM, Ryu S, and Yoon BW. Ischemic preconditioning enhances neurogenesis in the sub-ventricular zone. Neuroscience 146: 1020-1031, 2007.
142. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayr-aktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, and Brines M. Derivatives of erythropoietin that are tissue protective but not erythro-poietic. Science 305: 239-242, 2004.
143. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, Kim JW, Yustein JT, Lee LA, and Dang CV. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25: 6225-6234, 2005.
144. Li QF, Zhu YS, and Jiang H. Isoflurane preconditioning activates HIF-1alpha, iNOS and Erk1/2 and protects against oxygen-glucose deprivation neuronal injury. Brain Res 1245: 26-35, 2008.
145. Li Y, Lu Z, Keogh CL, Yu SP, and Wei L. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 27: 1043-1054, 2007.
146. Li YX, Ding SJ, Xiao L, Guo W, and Zhan Q. Desferox-amine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull 24: 89-95, 2008.
147. Lin CH, Chen PS, and Gean PW. Glutamate preconditioning prevents neuronal death induced by combined oxygen-glucose deprivation in cultured cortical neurons. Eur J Pharmacol 589: 85-93, 2008.
148. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 79: 1431-1568, 1999.
149. Luo Y, Ma D, Ieong E, Sanders RD, Yu B, Hossain M, and Maze M. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology 109: 782-789, 2008.
150. Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, Hossain M, Maxwell PH, and Maze M. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1{alpha} activation. J Am Soc Nephrol 20: 713-1320, 2009.
151. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, Bronson RT, and Springer TA. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci USA 95: 9448-9453, 1998.
152. Ma YP, Ma MM, Cheng SM, Ma HH, Yi XM, Xu GL, and Liu XF. Intranasal
153. Mahon PC, Hirota K, and Semenza GL. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686, 2001.
154. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, and Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554, 2001.
155. Malhotra S, Savitz SI, Ocava L, and Rosenbaum DM. Is-chemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack. J Neurosci Res 83: 19-27, 2006.
156. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, and Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 1: 393-399, 2005.
157. Mark KS and Davis TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 282: H1485-1494, 2002.
158. Marsden JT. Erythropoietin-Measurement and clinical applications. Ann Clin Biochem 43: 97-104, 2006.
159. Marti HH, Bernaudin M, Petit E, and Bauer C. Neuropro-tection and angiogenesis: Dual role of erythropoietin in brain ischemia. News Physiol Sci 15: 225-229, 2000.
160. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicay-lioglu M, Henn V, Yonekawa Y, Bauer C, and Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8: 666-676, 1996.
161. Matchett GA, Allard MW, Martin RD, and Zhang JH. Neuroprotective effect of volatile anesthetic agents: Molecular mechanisms. Neurol Res 31: 128-134, 2009.
162. Matsushita H, Johnston MV, Lange MS, and Wilson MA. Protective effect of erythropoietin in neonatal hypoxic ischemia in mice. Neuroreport 14: 1757-1761, 2003.
163. Mattson MP, Goodman Y, Luo H, Fu W, and Furukawa K. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: Evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 49: 681-697, 1997.
164. Maulik N, Sato M, Price BD, and Das DK. An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP ki-nase regulation of myocardial adaptation to ischemia. FEBS Lett 429: 365-369, 1998.
165. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent prote-olysis. Nature 399: 271-275, 1999.
166. McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, and Aizenman E. Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci USA 100: 715-720, 2003.
167. Miller BA, Perez RS, Shah AR, Gonzales ER, Park TS, and Gidday JM. Cerebral protection by hypoxic preconditioning in a murine model of focal ischemia-reperfusion. Neu-roreport 12: 1663-1669, 2001.
168. Milosevic J, Adler I, Manaenko A, Schwarz SC, Walk-inshaw G, Arend M, Flippin LA, Storch A, and Schwarz J. Nonhypoxic stabilization of hypoxia-inducible factor alpha (HIF-alpha): Relevance in neural progenitor/stem cells. Neurotox Res 15: 367-380, 2009.
169. Misgeld U and Frotscher M. Dependence of the viability of neurons in hippocampal slices on oxygen supply. Brain Res Bull 8: 95-100, 1982.
170. Mitic LL and Anderson JM. Molecular architecture of tight junctions. Annu Rev Physiol 60: 121-142, 1998.
171. Miyashita K, Itoh H, Arai H, Suganami T, Sawada N, Fu-kunaga Y, Sone M, Yamahara K, Yurugi-Kobayashi T, Park K, Oyamada N, Taura D, Tsujimoto H, Chao TH, Tamura N, Mukoyama M, and Nakao K. The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in is-chemic brain and its therapeutic potential. Endocrinology 147: 1642-1653, 2006.
172. Morishita E, Masuda S, Nagao M, Yasuda Y, and Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76: 105-116, 1997.
173. Morrison SJ, Csete M, Groves AK, Melega W, Wold B, and Anderson DJ. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J Neurosci 20: 7370-7376, 2000.
174. Muller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RH, and Bloch W. Role of erythropoietin for angiogenesis and vasculogenesis: From embryonic development through adulthood. Am J Physiol Heart Circ Physiol 290: H331-340, 2006.
175. Murakami K, Kondo T, Kawase M, Li Y, Sato S, Chen SF, and Chan PH. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci 18: 205-213, 1998.
176. Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hatano O, Kawahara N, Tamura A, Kirino T, and Nakafuku M. Regeneration of hippocampal pyramidal neurons after ische-mic brain injury by recruitment of endogenous neural progenitors. Cell 110: 429-441, 2002.
177. Naylor M, Bowen KK, Sailor KA, Dempsey RJ, and Ve-muganti R. Preconditioning-induced ischemic tolerance stimulates growth factor expression and neurogenesis in adult rat hippocampus. Neurochem Int 47: 565-572, 2005.
178. Nitatori T, Sato N, Waguri S, Karasawa Y, Araki H, Shi-banai K, Kominami E, and Uchiyama Y. Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J Neu-rosci 15: 1001-1011, 1995.
179. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, and Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161: 653-660, 2003.
180. O'Duffy AE, Bordelon YM, and McLaughlin B. Killer proteases and little strokes-How the things that do not kill you make you stronger. J Cereb Blood Flow Metab 27: 655-668, 2007.
181. Ohtsuki S, Sato S, Yamaguchi H, Kamoi M, Asashima T, and Terasaki T. Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. J Cell Physiol 210: 81-86, 2007.
182. Ohtsuki T, Matsumoto M, Kuwabara K, Kitagawa K, Suzuki K, Taniguchi N, and Kamada T. Influence of oxidative stress on induced tolerance to ischemia in gerbil hippo-campal neurons. Brain Res 599: 246-252, 1992.
183. Ohtsuki T, Ruetzler CA, Tasaki K, and Hallenbeck JM. Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons. J Cereb Blood Flow Metab 16: 1137-1142, 1996.
184. Okuda T, Tagawa K,Qi ML, Hoshio M, Ueda H,Kawano H, Kanazawa I, Muramatsu M, and Okazawa H. Oct-3/4 repression accelerates differentiation of neural progenitor cells in vitro and in vivo. Brain Res Mol Brain Res 132: 18-30, 2004.
185. Ozer A, Wu LC, and Bruick RK. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci USA 102: 7481-7486, 2005.
186. Panahian N, Yoshiura M, and Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem 72: 1187-1203, 1999.
187. Papandreou I, Cairns RA, Fontana L, Lim AL, and Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187-197, 2006.
188. Parks DA and Granger DN. Xanthine oxidase: Biochemistry, distribution and physiology. Acta Physiol Scand Suppl 548: 87-99, 1986.
189. Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, and Lee FS. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358: 162-168, 2008.
190. Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, McMullin MF, and Lee FS. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 103: 654-659, 2006.
191. Petito CK, Feldmann E, Pulsinelli WA, and Plum F. Delayed hippocampal damage in humans following cardio-respiratory arrest. Neurology 37: 1281-1286, 1987.
192. Petty MA and Lo EH. Junctional complexes of the blood-brain barrier: Permeability changes in neuroinflammation. Prog Neurobiol 68: 311-323, 2002.
193. Piantadosi CA and Zhang J. Mitochondrial generation of reactive oxygen species after brain ischemia in the rat. Stroke 27: 327-331; discussion 332, 1996.
194. Plate KH, Beck H, Danner S, Allegrini PR, and Wiessner C. Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral in-farct. J Neuropathol Exp Neurol 58: 654-666, 1999.
195. Prass K, Ruscher K, Karsch M, Isaev N, Megow D, Priller J, Scharff A, Dirnagl U, and Meisel A. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 22: 520-525, 2002.
196. Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, Kapinya K, Dirnagl U, and Meisel A. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34: 1981-1986, 2003.
197. Pulsinelli WA, Brierley JB, and Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 11: 491-498, 1982.
198. Ran R, Xu H, Lu A, Bernaudin M, and Sharp FR. Hypoxia preconditioning in the brain. Dev Neurosci 27: 87-92, 2005.
199. Ratan RR, Siddiq A, Aminova L, Langley B, McCo-noughey S, Karpisheva K, Lee HH, Carmichael T, Kornblum H, Coppola G, Geschwind DH, Hoke A, Smirnova N, Rink C, Roy S, Sen C, Beattie MS, Hart RP, Grumet M, Sun D, Freeman RS, Semenza GL, and Gazaryan I. Small molecule activation of adaptive gene expression: Tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann NY Acad Sci 1147: 383-394, 2008.
200. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, and Colgan SP. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134: 145-155, 2008.
201. Rosenberg GA and Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 22: E4, 2007.
202. Rosenberger C, Rosen S, Shina A, Frei U, Eckardt KU, Flippin LA, Arend M, Klaus SJ, and Heyman SN. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant 23: 3472-3478, 2008.
203. Rothman SM and Olney JW. Glutamate and the patho-physiology of hypoxic-ischemic brain damage. Ann Neurol 19: 105-111, 1986.
204. Ryan HE, Lo J, and Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998.
205. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, and Sasaki R. In vivo evidence that erythropoi-etin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95: 4635-4640, 1998.
206. Sandoval KE and Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 32: 200-219, 2008.
207. Saver JL, Kidwell C, Eckstein M, and Starkman S. Pre-hospital neuroprotective therapy for acute stroke: Results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 35: e106-108, 2004.
208. Schaller B. Ischemic preconditioning as induction of is-chemic tolerance after transient ischemic attacks in human brain: Its clinical relevance. Neurosci Lett 377: 206-211, 2005.
209. Schiemanck SK, Post MW, Witkamp TD, Kappelle LJ, and Prevo AJ. Relationship between ischemic lesion volume and functional status in the 2nd week after middle cerebral artery stroke. Neurorehabil Neural Repair 19: 133-138, 2005.
210. Schmidt-Kastner R and Freund TF. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience 40: 599-636, 1991.
211. Schneider C, Krischke G, Keller S, Walkinshaw G, Arend M, Rascher W, Gassmann M, and Trollmann R. Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain. Brain Res 1280: 43-51, 2009.
212. Schonemeier B, Schulz S, Hoellt V, and Stumm R. Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J Neuroimmunol 198: 39-45, 2008.
213. Semenza GL, Jiang BH, Leung SW, Passantino R, Con-cordet JP, Maire P, and Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehy-drogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996.
214. Semenza GL, Nejfelt MK, Chi SM, and Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 88: 5, 1991.
215. Semenza GL and Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
216. Serrano J, Alonso D, Encinas JM, Lopez JC, Fernandez AP, Castro-Blanco S, Fernandez-Vizarra P, Richart A, Bentura ML, Santacana M, Uttenthal LO, Cuttitta F, Rodrigo J, and Martinez A. Adrenomedullin expression is up-regulated by ischemia-reperfusion in the cerebral cortex of the adult rat. Neuroscience 109: 717-731, 2002.
217. Shigeno T, Mima T, Takakura K, Graham DI, Kato G, Hashimoto Y, and Furukawa S. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. J Neurosci 11: 2914-2919, 1991.
218. Shingo T, Sorokan ST, Shimazaki T, and Weiss S. Ery-thropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21: 9733-9743, 2001.
219. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, La-Manna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280: 41732-41743, 2005.
220. Silva M, Grillot D, Benito A, Richard C, Nunez G, and Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88: 1576-1582, 1996.
221. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, and Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98: 4044-4049, 2001.
222. Soares MP, Seldon MP, Gregoire IP, Vassilevskaia T, Ber-berat PO, Yu J, Tsui TY, and Bach FH. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol 172: 3553-3563, 2004.
223. Sorond FA and Ratan RR. Ironing-out mechanisms of neuronal injury under hypoxic-ischemic conditions and potential role of iron chelators as neuroprotective agents. Antioxid Redox Signal 2: 421-436, 2000.
224. Soucek T, Cumming R, Dargusch R, Maher P, and Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 39: 43-56, 2003.
225. Storch A, Paul G, Csete M, Boehm BO, Carvey PM, Kupsch A, and Schwarz J. Long-term proliferation and dopami-nergic differentiation of human mesencephalic neural pre cursor cells. Exp Neurol 170: 317-325, 2001.
226. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, and Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15: 2445-2453, 2001.
227. Studer L, Csete M, Lee SH, Kabbani N, Walikonis J, Wold B, and McKay R. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 20: 7377-7383, 2000.
228. Stumm RK, Rummel J, Junker V, Culmsee C, Pfeiffer M, Krieglstein J, Hollt V, and Schulz S. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: Isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci 22: 5865-5878, 2002.
229. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, and Greenberg DA. VEGF-induced neuroprotection, neuro-genesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111: 1843-1851, 2003.
230. Sun Y, Zhou C, Polk P, Nanda A, and Zhang JH. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab 24: 259-270, 2004.
231. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T, and Tohyama M. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem 274: 8531-8538, 1999.
232. Tang Y, Pacary E, Freret T, Divoux D, Petit E, Schumann-Bard P, and Bernaudin M. Effect of hypoxic precondition-ing on brain genomic response before and following ischemia in the adult mouse: Identification of potential neuroprotective candidates for stroke. Neurobiol Dis 21: 18-28, 2006.
233. Theus MH, Wei L, Cui L, Francis K, Hu X, Keogh C, and Yu SP. In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain. Exp Neurol 210: 656-670, 2008.
234. Tian H, McKnight SL, and Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997.
235. Tixier E, Leconte C, Touzani O, Roussel S, Petit E, and Bernaudin M. Adrenomedullin protects neurons against oxygen glucose deprivation stress in an autocrine and paracrine manner. J Neurochem 106: 1388-1403, 2008.
236. Trump BF and Berezesky IK. Calcium-mediated cell injury and cell death. FASEB J 9: 219-228, 1995.
237. Tsukita S, Furuse M, and Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2: 285-293, 2001.
238. Van Itallie CM and Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 68: 403-429, 2006.
239. Van Itallie CM, Fanning AS, and Anderson JM. Reversal of charge selectivity in cation or anion-selective epithelial lines by expression of different claudins. Am J Physiol Renal Physiol 285: F1078-1084, 2003.
240. van Lookeren Campagne M, Thibodeaux H, van Bruggen N, Cairns B, Gerlai R, Palmer JT, Williams SP, and Lowe DG. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci USA 96: 12870-12875, 1999.
241. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, and Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198: 971-975, 2003.
242. Wagener FA, da Silva JL, Farley T, de Witte T, Kappas A, and Abraham NG. Differential effects of heme oxygenase isoforms on heme mediation of endothelial intracellular adhesion molecule 1 expression. J Pharmacol Exp Ther 291: 416-423, 1999.
243. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS hetero-dimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
244. Wang ZL, Cheng SM, Ma MM, Ma YP, Yang JP, Xu GL, and Liu XF. Intranasally delivered bFGF enhances neuro-genesis in adult rats following cerebral ischemia. Neurosci Lett 446: 30-35, 2008.
245. Watanabe K, Takayasu M, Noda A, Hara M, Takagi T, Suzuki Y, and Yoshia J. Adrenomedullin reduces ischemic brain injury after transient middle cerebral artery occlusion in rats. Acta Neurochir (Wien) 143: 1157-1161, 2001. (Pubitemid 33078443)
246. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, and Einhaupl KM. Attenuated stroke severity after prodromal TIA: A role for ischemic tolerance in the brain? Stroke 30: 1851-1854, 1999.
247. Weisbrot-Lefkowitz M, Reuhl K, Perry B, Chan PH, Inouye M, and Mirochnitchenko O. Overexpression of human glutathione peroxidase protects transgenic mice against focal cerebral ischemia/reperfusion damage. Brain Res Mol Brain Res 53: 333-338, 1998. (Pubitemid 28085473)
248. Weiss N, Miller F, Cazaubon S, and Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788: 842-857, 2009.
249. Wen TC, Sadamoto Y, Tanaka J, Zhu PX, Nakata K, Ma YJ, Hata R, and Sakanaka M. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 67: 795-803, 2002.
250. Wen TC, Tanaka J, Peng H, Desaki J, Matsuda S, Maeda N, Fujita H, Sato K, and Sakanaka M. Interleukin 3 prevents delayed neuronal death in the hippocampal CA1 field. J Exp Med 188: 635-649, 1998.
251. Whitman EM, Pisarcik S, Luke T, Fallon M, Wang J, Sylvester JT, Semenza GL, and Shimoda LA. Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K+ channel expression in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 294: L309-318, 2008.
252. Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, and Schulz JB. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 22: 6401-6407, 2002.
253. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, and Eckardt KU. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17: 271-273, 2003.
254. Willis D, Moore AR, Frederick R, and Willoughby DA. Heme oxygenase: A novel target for the modulation of the inflammatory response. Nat Med 2: 87-90, 1996.
255. Witt KA, Mark KS, Hom S, and Davis TP. Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 285: H2820-H2831, 2003.
256. Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2: 120-128, 2005.
257. Xia CF, Yin H, Borlongan CV, Chao J, and Chao L. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther 15: 1243-1254, 2004.
258. Xia CF, Yin H, Borlongan CV, Chao J, and Chao L. Post-ischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol 197: 521-530, 2006. (Pubitemid 43077160)
259. Xue H, Guo H, Li YC, and Hao ZM. Heme oxygenase-1 induction by hemin protects liver cells from ischemia/reperfusion injury in cirrhotic rats. World J Gastroenterol 13: 5384-5390, 2007.
260. Yamada K, Ji JJ, Yuan H, Miki T, Sato S, Horimoto N, Shimizu T, Seino S, and Inagaki N. Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 292: 1543-1546, 2001.
261. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, and Yasuhara H. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29: 12-17, 1998.
262. Yang G, Chan PH, Chen J, Carlson E, Chen SF, Weinstein P, Epstein CJ, and Kamii H. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfu-sion injury after focal cerebral ischemia. Stroke 25: 165-170, 1994.
263. Yang ZJ, Bao WL, Qiu MH, Zhang LM, Lu SD, Huang YL, and Sun FY. Role of vascular endothelial growth factor in neuronal DNA damage and repair in rat brain following a transient cerebral ischemia. J Neurosci Res 70: 140-149, 2002.
264. Yano A, Shingo T, Takeuchi A, Yasuhara T, Kobayashi K, Takahashi K, Muraoka K, Matsui T, Miyoshi Y, Hamada H, and Date I. Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and an-giogenic effects on focal cerebral ischemia. J Neurosurg 103: 104-114, 2005.
265. Yeh WL, Lu DY, Lin CJ, Liou HC, and Fu WM. Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression. Mol Pharmacol 72: 440-449, 2007.
266. Yeung SJ, Pan J, and Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis-The seventh hallmark of cancer. Cell Mol Life Sci 65: 3981-3999, 2008.
267. Yoshida D, Kim K, Noha M, and Teramoto A. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 76: 13-21, 2006.
268. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, and Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol. 275: 8, 1998.
269. Zeynalov E, Shah ZA, Li RC, and Dore S. Heme oxygenase 1 is associated with ischemic preconditioning-induced protection against brain ischemia. Neurobiol Dis 35: 264-269, 2009.
270. Zhang F, Signore AP, Zhou Z, Wang S, Cao G, and Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: Potential signaling mechanisms. J Neurosci Res 83: 1241-1251, 2006.
271. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, and Semenza GL. Mi-tochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283: 10892-10903, 2008.
272. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, and Semenza GL. HIF-1 inhibits mi-tochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420, 2007.
273. Zhang J, Yang ZJ, Klaus JA, Koehler RC, and Huang J. Delayed tolerance with repetitive transient focal ischemic preconditioning in the mouse. Stroke 39: 967-974, 2008.
274. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, and Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106: 829-838, 2000.
275. Zhao H, Sapolsky RM, and Steinberg GK. Interrupting re-perfusion as a stroke therapy: ischemic postconditioning reduces infarct size after focal ischemia in rats. J Cereb Blood Flow Metab 26: 1114-1121, 2006.
276. Zhao P and Zuo Z. Isoflurane preconditioning induces neuroprotection that is inducible nitric oxide synthase-dependent in neonatal rats. Anesthesiology 101: 695-703, 2004.
277. Zheng S and Zuo Z. Isoflurane preconditioning reduces purkinje cell death in an in vitro model of rat cerebellar ischemia. Neuroscience 118: 99-106, 2003.
278. Zheng S and Zuo Z. Isoflurane preconditioning induces neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases. Mol Pharmacol 65: 1172-1180, 2004.
279. Zhu Y, Zhang Y, Ojwang BA, Brantley MA, Jr., and Gidday JM. Long-term tolerance to retinal ischemia by repetitive hypoxic preconditioning: Role of HIF-1alpha and heme oxygenase-1. Invest Ophthalmol Vis Sci 48: 1735-1743, 2007.
280. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, and Littman DR. Function of the chemokine receptor CXCR4 in hae-matopoiesis and in cerebellar development. Nature 393: 595-599, 1998.